extending natalizumab's use without increasing risk to patients
Published 9 years ago • 210 plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
2:06
extending natalizumab's use without increasing risk to ms patients
-
8:18
risk analysis of natalizumab in progressive multifocal leukoencephalopathy
-
0:56
is tysabri for ms dangerous during covid19 pandemic? #shorts
-
10:21
additional insights from natalizumab treatment in ms
-
2:03
risk of pml in patients taking natalizumab
-
21:01
tysabri pml risk & extended interval dosing
-
8:12
turning to tysabri first
-
6:27
evaluating natalizumab’s risk-benefit profile in ms
-
42:10
dr paul molyneux - managing pml risk in patients treated with natalizumab.
-
2:14
multiple sclerosis: early treatment with tecfidera and tysabri can improve outcomes
-
1:55
monitoring a patient on natalizumab for jc virus
-
13:35
tysabri side effects explained by neurologist
-
3:10
natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active ms
-
9:21
what you need to know about natalizumab (tysabri®)
-
2:18
next-ms: personalized extended interval dosing of natalizumab in rrms
-
0:19
you need more anesthesia... 🌱
-
29:26
bench to bedside: multiple sclerosis and tysabri, part 2 - ted yednock
-
7:33
comparing exit strategies in natalizumab-responders at high risk for pml
-
14:49
“choosing the right disease-modifying therapy,” geeta ganesh, m.d.